List of Excipients in Branded Drug CLORAZEPATE DIPOTASSIUM

Generic Drugs Containing CLORAZEPATE DIPOTASSIUM

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	clorazepate dipotassium	0378-0030	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	clorazepate dipotassium	0378-0030	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	clorazepate dipotassium	0378-0030	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	clorazepate dipotassium	0378-0030	MAGNESIUM OXIDE

What are the Most Frequently-Used Excipients in CLORAZEPATE DIPOTASSIUM?

# Of NDCs	Excipient
18	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
7	CROSCARMELLOSE SODIUM
4	D&C RED NO. 6 BARIUM LAKE

Clorazepate Dipotassium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Clorazepate dipotassium is an established, genericized benzodiazepine prodrug with limited opportunity for exclusivity based on the active ingredient itself. Commercial value is concentrated in low-cost immediate-release oral products, supply reliability, dosage-form differentiation, pediatric and geriatric usability, and controlled-substance compliance. The strongest formulation strategy is a conventional, robust tablet platform using excipients that protect dose uniformity, mechanical strength, disintegration, and long-term chemical stability.

What is clorazepate dipotassium and how is it formulated?

Clorazepate dipotassium is the dipotassium salt of clorazepate, a prodrug that converts rapidly in gastric acid to desmethyldiazepam, also known as nordazepam. It is approved for anxiety disorders, adjunctive therapy in partial seizures, and acute alcohol withdrawal symptoms.[1]

The U.S. product is primarily an immediate-release oral tablet. Marketed strengths have included 3.75 mg, 7.5 mg, and 15 mg clorazepate dipotassium. The drug is administered in low milligram quantities, which makes blend uniformity, segregation control, and content-uniformity testing central manufacturing issues.

Attribute	Commercial implication
Active ingredient	Clorazepate dipotassium
Pharmacology	Benzodiazepine prodrug converted to desmethyldiazepam
Primary dosage form	Immediate-release tablet
Typical strengths	3.75 mg, 7.5 mg, 15 mg
U.S. regulatory category	Prescription drug; Schedule IV controlled substance
Core market	Generic oral benzodiazepine
Main formulation challenge	Low-dose uniformity and chemical stability
Main commercial constraint	Mature market, controlled-substance restrictions, generic pricing

Clorazepate is not a biologic, so biosimilar analysis does not apply. The relevant competitors are other benzodiazepines, including diazepam, lorazepam, clonazepam, oxazepam, and chlordiazepoxide.

What excipients are appropriate for clorazepate dipotassium tablets?

A conventional direct-compression or dry-granulation platform is commercially attractive. The final selection must be supported by compatibility, dissolution, stability, and process-validation data because excipient suitability depends on grade, moisture level, manufacturing conditions, and packaging.

Recommended excipient functions

Formulation function	Candidate excipients	Commercial rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Supports tablet mass and content uniformity
Dry binder	Microcrystalline cellulose, pregelatinized starch, copovidone	Improves compactibility at low API loading
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports immediate release
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces weight variation
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling adhesion
Colorant	Iron oxides or approved lake pigments	Supports strength identification and error reduction
Film coating	Hypromellose, polyethylene glycol, titanium dioxide where permitted	Improves handling, swallowability, and visual differentiation
Sweetener or flavor	Sucralose, saccharin sodium, flavor system	Relevant to dispersible or liquid products

The simplest commercial platform is a lactose or microcrystalline-cellulose tablet with croscarmellose sodium or crospovidone, colloidal silicon dioxide, and magnesium stearate. A film coat can distinguish strengths and reduce tablet dusting without materially changing the immediate-release profile.

Which excipient risks require early testing?

Low-dose benzodiazepine products require tighter control of powder behavior than their small tablet size may suggest. Key risks include:

1. API segregation during transfer and compression.
2. Over-lubrication from excessive magnesium stearate or prolonged blending.
3. Moisture-driven changes in tablet hardness, disintegration, or chemical stability.
4. Adsorption or poor recovery during analytical sample preparation.
5. Dissolution changes caused by hydrophobic coating or lubricant concentration.
6. Colorant and coating differences that complicate strength identification.

A blend-uniformity study should evaluate the full commercial batch scale, not only laboratory mixtures. The process should use controlled particle-size distributions, low-transfer-drop heights, validated blend endpoints, and packaging that limits moisture exposure.

What formulations are protected by clorazepate patents?

The active ingredient is an old small molecule, and the original product-level exclusivity has expired. The commercial market is therefore driven by abbreviated new drug applications and established manufacturing know-how rather than meaningful composition-of-matter protection.

Potentially protectable subject matter includes:

• Orally disintegrating tablets.
• Low-dose tablets with improved content uniformity.
• Taste-masked powders or granules.
• Unit-dose sachets for institutional use.
• Liquid or suspension formulations.
• Modified-release systems.
• Stabilized compositions with defined moisture limits.
• Specific particle-size distributions.
• Continuous manufacturing or low-shear blending processes.
• Packaging systems that extend shelf life.

A new patent would need a credible technical effect. A claim covering clorazepate dipotassium plus routine excipients would face substantial obviousness and enablement risk. Stronger candidates would demonstrate unexpected stability, dissolution, dose uniformity, abuse-deterrence performance, or a clinically useful delivery advantage.

When does clorazepate dipotassium lose exclusivity?

Clorazepate dipotassium has already lost the exclusivity associated with the original drug approval. The U.S. product has been available for decades, and generic competition is established.

Exclusivity category	Status
Original drug exclusivity	Expired
Composition-of-matter protection	Expired
Current generic pathway	ANDA under section 505(j)
Pediatric exclusivity	No commercially relevant current protection identified
Orphan exclusivity	Not applicable to the established product
Biologic exclusivity	Not applicable
Controlled-substance restrictions	Remain applicable despite patent expiry

The absence of active core exclusivity does not eliminate regulatory barriers. An applicant must still demonstrate pharmaceutical equivalence, bioequivalence, manufacturing quality, stability, labeling compliance, and controlled-substance controls.

What is the Orange Book status of clorazepate dipotassium?

FDA Orange Book treatment is relevant to the reference product and listed products, but it does not create a new commercial barrier for an old molecule. The principal questions for an ANDA applicant are whether the reference listed drug is active, whether patents or exclusivity are listed, and whether the proposed product matches the reference product’s dosage form, strength, route, and labeling requirements.[2]

Because clorazepate products are mature prescription products, an applicant is more likely to face ordinary ANDA requirements than a substantial Orange Book patent challenge. A current product-specific Orange Book and FDA Drugs@FDA review is required to confirm the live reference listing, any listed patents, and the approved strengths at the time of filing.

Are Paragraph IV challenges relevant to clorazepate dipotassium?

Paragraph IV certification is legally available when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For clorazepate dipotassium, the commercial relevance is likely limited because the original product and core active-ingredient protection are long expired.

The greater risk is procedural rather than substantive:

• A listed formulation or method-of-use patent could create a 30-month stay if a timely infringement action is filed.
• A withdrawn or discontinued reference product could complicate ANDA pathway selection.
• Labeling differences could trigger a section viii carve-out issue.
• Controlled-substance requirements could delay approval or launch even without patent litigation.

No meaningful current Paragraph IV litigation position should be assumed without checking the FDA Orange Book and the Federal Court docket for the specific reference product.

What manufacturing and excipient barriers affect market entry?

The main barriers are execution and quality, not active-ingredient patent rights.

API and supply-chain risks

Clorazepate dipotassium is a low-volume, mature API. That can create supplier-concentration risk, minimum-order constraints, and inconsistent lead times. The API supplier should be qualified for:

• Identity and assay.
• Related substances and degradation products.
• Residual solvents.
• Water content.
• Particle-size distribution.
• Polymorphic or solid-state consistency.
• Elemental impurities.
• Nitrosamine risk assessment where applicable.

The manufacturing process also involves a benzodiazepine controlled substance. Facilities must maintain appropriate DEA registration, inventory reconciliation, security controls, loss reporting, and recordkeeping.[3]

Tablet-process risks

Direct compression is economically attractive but may produce inadequate uniformity if the API has poor flow or a wide particle-size distribution. Dry granulation can improve flow and reduce segregation, though it adds process complexity and may affect dissolution.

Wet granulation should not be selected by default. It introduces water and drying exposure that may increase chemical risk or alter tablet performance. It can still be justified if the API-excipient blend cannot meet content-uniformity and mechanical-strength requirements through direct compression or dry granulation.

What commercial opportunities exist for clorazepate dipotassium?

The core generic tablet opportunity is likely low-margin. Higher-value opportunities require a differentiated customer or delivery proposition.

1. Reliable generic supply

Shortages or supplier withdrawals can create temporary value even in a mature market. A second-source strategy based on dual API suppliers, safety stock, and validated alternate excipient grades can support hospital, wholesaler, and government-contract business.

2. Strength-specific packaging

Color-coded, calendarized, or unit-dose packaging can reduce dispensing errors across 3.75 mg, 7.5 mg, and 15 mg strengths. Packaging claims must remain consistent with approved labeling and cannot imply clinical superiority without evidence.

3. Geriatric and institutional usability

An easy-to-swallow film-coated tablet, scored tablet where technically and regulatorily supportable, or unit-dose blister can address nursing-home and hospital workflow needs. A smaller tablet may improve swallowability, but reducing tablet size can worsen content-uniformity risk.

4. Pediatric-oriented delivery

A pharmacy-compounded liquid is not equivalent to an FDA-approved commercial liquid. A sponsor could investigate a ready-to-use oral suspension, powder for reconstitution, or dispersible tablet. The principal technical challenges are taste, sedimentation, dose uniformity after shaking, preservative compatibility, and in-use stability.

5. Orally disintegrating tablet

An orally disintegrating tablet could provide a meaningful dosage-form distinction. The formulation would require rapid disintegration, acceptable taste, adequate mechanical strength, and robust packaging against humidity. A novel ODT patent would need more than the routine substitution of crospovidone or mannitol.

6. Regional licensing

Licensing an established formulation to a regional generic company may be more realistic than pursuing a global launch. Opportunities are strongest in markets where benzodiazepine products remain reimbursed and where local registration, controlled-drug distribution, or supply access creates a barrier to entry.

How does clorazepate compare with competing benzodiazepines?

Drug	Typical commercial position	Formulation opportunity	Competitive issue
Clorazepate	Long-acting prodrug; mature generic	ODT, liquid, unit-dose tablet	Small and price-sensitive market
Diazepam	Broad indications and multiple dosage forms	Rectal, injectable, oral liquid	Larger established competitor
Lorazepam	Anxiety, seizures, procedural use	Sublingual and parenteral products	Strong hospital and acute-care presence
Clonazepam	Seizure and panic-disorder use	ODT and conventional tablets	Established brand recognition
Chlordiazepoxide	Alcohol withdrawal and anxiety	Capsules and combination use	Competes in withdrawal protocols
Oxazepam	Anxiety and withdrawal	Conventional oral products	Slower-onset positioning

Clorazepate’s differentiation is pharmacokinetic and therapeutic rather than formulation-based. Its conversion to desmethyldiazepam produces a long-acting active metabolite. That characteristic can support prescriber familiarity but also raises concerns about accumulation, sedation, dependence, and prolonged impairment. FDA labeling carries class warnings for abuse, misuse, addiction, physical dependence, and withdrawal reactions.[1]

What litigation and settlement risks affect clorazepate?

No major current patent-litigation thesis should be assigned to clorazepate without a live docket and Orange Book review. The more material legal risks are:

• Controlled-substance compliance failures.
• Product-liability claims involving dependence, withdrawal, overdose, or impaired driving.
• Manufacturing deviations affecting assay or content uniformity.
• Labeling claims involving prolonged metabolite exposure.
• Contract disputes over API supply and regulatory responsibility.
• State and federal scrutiny of benzodiazepine distribution.

Settlement agreements are unlikely to be a central market factor unless a newly developed dosage form or formulation patent creates a specific dispute. For a conventional generic tablet, launch timing is more likely to depend on FDA approval, manufacturing readiness, and commercial economics.

What FDA regulatory pathway applies to a new product?

A conventional generic tablet would generally proceed through an ANDA if it is pharmaceutically equivalent and bioequivalent to the reference listed drug. A materially different dosage form, strength, route, or formulation may require a suitability petition, a 505(b)(2) application, or another regulatory strategy depending on the product design.[2]

A sponsor developing a liquid, ODT, or modified-release product should expect additional work on:

• Comparative dissolution.
• Bioequivalence methodology.
• Food-effect assessment where relevant.
• In-use stability.
• Microbial limits and preservative effectiveness for aqueous products.
• Device or dosing-measure validation.
• Abuse, misuse, and diversion controls.
• Human factors for institutional or pediatric packaging.

How strong is the patent estate for clorazepate dipotassium?

The core patent estate is weak from a market-exclusivity perspective because the active ingredient and original product are old. A new entrant can still create a narrow defensive estate around a technically differentiated formulation, but patent value will depend on measurable performance and enforceable claim scope.

Patent category	Expected strength
Original active-ingredient patent	Expired
Conventional tablet with standard excipients	Weak
Specific ODT or taste-masked platform	Moderate if data-supported
Novel liquid or suspension	Moderate if stability and dosing advantages are demonstrated
Packaging-only claims	Usually limited
Manufacturing process claims	Moderate where process control is difficult to replicate
Method-of-use claims	Limited unless tied to a new, patent-eligible use

What generic launch scenarios exist?

Low-cost conventional tablet

This is the fastest and least differentiated route. It requires efficient API sourcing, validated blend uniformity, competitive packaging, and disciplined controlled-substance operations. Gross margins may be constrained by multiple generic suppliers.

Premium availability product

A sponsor could target hospitals, long-term-care facilities, or public-sector purchasers with guaranteed supply, unit-dose packaging, and multiple strengths. The premium would depend on demonstrated supply reliability rather than patent protection.

Differentiated dosage form

An ODT, oral suspension, or dispersible tablet could support a 505(b)(2) or other differentiated strategy. Development cost and regulatory complexity would be higher, but competition may be narrower.

Regional commercialization

A local partner could manage controlled-substance distribution, reimbursement, and registration. The licensor could provide formulation, analytical methods, and supply while avoiding a fully integrated commercial buildout.

Key Takeaways

• Clorazepate dipotassium is a mature, genericized benzodiazepine prodrug with no meaningful core exclusivity remaining.
• The best base formulation is a robust immediate-release tablet using conventional diluents, disintegrants, glidants, and lubricants.
• Low-dose blend uniformity, API particle-size control, moisture management, and controlled-substance compliance are the main execution risks.
• Commercial opportunities are strongest in supply reliability, institutional packaging, ODTs, oral liquids, and regional licensing.
• A routine excipient combination is unlikely to support valuable patent protection without unexpected technical results.
• Biosimilar risk is irrelevant because clorazepate dipotassium is a small-molecule drug.
• Paragraph IV risk is likely limited for a conventional generic, but current Orange Book listings must be checked before launch planning.
• Product liability, dependence warnings, diversion controls, and manufacturing compliance remain material risks after patent expiry.

FAQs

Is clorazepate dipotassium still commercially attractive?

Only selectively. Conventional tablets are likely to be price-sensitive, while differentiated dosage forms and reliable institutional supply may support better margins.

Can clorazepate dipotassium be formulated as an oral liquid?

Yes, but the product would require dedicated stability, dose-uniformity, microbial, preservative, taste, and in-use testing. It would not automatically qualify as an ordinary generic tablet product.

Does clorazepate dipotassium require a biosimilar application?

No. It is a small-molecule drug. A conventional equivalent would generally use an ANDA pathway, subject to FDA reference-product and bioequivalence requirements.

Which excipient is most important for clorazepate tablet performance?

No single excipient controls performance. The critical system is the combination of a compressible diluent, effective disintegrant, controlled lubricant level, and flow aid, supported by a validated blending process.

Can a new clorazepate formulation receive patent protection?

Potentially, but protection would need to rest on a specific formulation or process that produces a credible, non-obvious technical benefit, such as improved stability, dose uniformity, rapid disintegration, or clinically useful delivery.

References

1. U.S. Food and Drug Administration. (2023). Clorazepate dipotassium prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Drug Enforcement Administration. (2024). Drug scheduling and controlled-substance requirements. U.S. Department of Justice.

4. U.S. Food and Drug Administration. (2018). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.